Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Dendreon

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Dendreon's 2012 oncology sales performance.

Dendreon Corporation

BMS appoints new commercial leader, Davies joins Eisai and more

BMS appoints new commercial leader, Davies joins Eisai and more

He has also held a number of roles for Dendreon Corporation and Roche’s Genentech, where he worked on its Avastin franchise strategy.

Cancer immunotherapy: What's on the horizon?

Cancer immunotherapy: What's on the horizon? Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and Antigenics’ Oncophage, commercially they haven’t yet made much impact and the pipeline has been

Dendreon appoints new R&D lead

Dendreon appoints new R&D lead Cancer vaccine company Dendreon has added to its senior team, appointing Dr Bruce Brown as its new senior vice president, medical. ... Dr Brown’s new role will see him head the company’s R&D organisation, including research and discovery, clinical

Deal Watch January 2017

Deal Watch January 2017 Bringing in an additional $819.9m in cash, Valeant also sold its equity interest in Dendreon (manufacturer of Provenge, a personalised immunotherapy) to the Sanpower Group. ... Dendreon had only been acquired in February 2015 from bankruptcy for $495m

Valeant uncouples Dendreon and skincare brands to cut debt

Valeant uncouples Dendreon and skincare brands to cut debt Agrees deals worth $2.1bn with L’Oreal and Sanpower Group. Dendreon's Provenge cancer vaccine. ... cosmetics giant L'Oreal for $1.3bn and the Dendreon cancer vaccine business to China's Sanpower Group for around $820m.

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics